Combatting Corruption and Promoting Equity in the Health Sector
Recommended Reading
Session 1
1.Svensson, Jakob. 2005. "Eight Questions About Corruption". Journal of Economic Perspectives, 19(3).
2. Paul M. Heywood and Jonathan Rose, “’Close but No Cigar’: The Measurement of Corruption.” Journal of Public Policy vol. 34, no. 3 (2014).
Session 3
1. Jillian Clare Kohler, Tomas Chang Pico, Taryn Vian, Tim K. Mackey. “The Global Wicked Problem of Corruption and Its Risks for Access to HIV/AIDS Medicines”. Clinical Pharmacology & Therapeutics 104(6) August 2018.
2. Anne Paschke, Deirdre Dimancesco, Taryn Vian, Jillian C Kohler & Gilles Forte. “Increasing transparency and accountability in national pharmaceutical systems”. Bulletin of the World Health Organization. 2018;96(11):782-791
3. Access to Medicine Index 2018, Market Influence & Compliance, p.48-55
4. Genovese L, Edwards D. Why It Matters - Pharmaceutical Compliance, Anti-Corruption and Access to Medicine.; 2017
5. Transparency International UK, Corruption in the pharmaceutical sector
Session 4
Walkowiak H, Hafner T, Putter S.J. 2018. Strengthening Governance in Pharmaceutical Systems:A Compendium of Country Case Studies. Submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program. Arlington, VA: Management Sciences for Health. (p 22-24)
Session 5
1. Seiter, A. (2010). A practical approach to pharmaceutical policy. The World Bank.
2. Diack, A., Seiter, A., Hawkins, L., & Dweik, I. S. (2010). Assessment of governance and corruption in the pharmaceutical sector: Lessons learned from low and middle income countries.
3. Hussman, K. (2011). Vulnerabilities to Corruption in the Health Sector: Perspectives from Latin American sub-sytems for the Poor. United Nations Development Programme. Panama.
